Pharmaceutical News

RSS

New drug may revolutionize how chronic iron overload is treated in chronic anemia patients

Those with severe chronic anemias need frequent blood transfusions to remain healthy, but such frequent transfusions can cause a potentially deadly buildup of iron in the body, leading to heart and liver failure. The traditional treatment to remove excess iron is so onerous that many patients choose to forgo it, putting their own lives at risk. The results of an international study on deferasirox, a new drug that may revolutionize the way chronic iron overload is treated, will be published in the May 1, 2006, issue of Blood, the official journal of the American Society of Hematology.

26 Apr 2006

Avian flu vaccine to be developed by Mount Sinai School of Medicine and Bionostra

The Mount Sinai School of Medicine will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.

26 Apr 2006

Enzyme research points to better drugs and improved industrial processes

Groundbreaking enzyme research could revolutionise the way drugs are made and have major implications for the industrial sector, including brewing, food processing, domestic cleaning and paper manufacturing.

From The University of Manchester 25 Apr 2006

Study shows drugs work differently in the brains of men and women

A Johns Hopkins discovery could lead to tailored treatments for drug abuse and neurological diseases after providing what is believed to be the first evidence in people that amphetamines have a greater effect on men's brains than women's.

24 Apr 2006

Research into toxins points to development of better medicines

Researchers have combined magnetic resonance spectroscopy with special protein synthesis procedures to uncover how potassium channels and toxins combine and change in structure. This work could make it possible to develop medications for high blood pressure and many other diseases connected to potassium channel failure .

23 Apr 2006

Concerns for inexpensive fertility drug appears to be unfounded

Concerns about the use of letrozole, an easy-to-use and inexpensive drug for the treatment of infertility, appear to be unfounded, according to a major study co-authored by Dr. Togas Tulandi, Director of Division of Reproductive Endocrinology and Infertility, McGill University Health Centre (MUHC) and Chief of Obstetrics and Gynecology at the Jewish General Hospital, and Professor of Obstetrics and Gynecology at McGill University.

23 Apr 2006

No support for medical use of marijuana from the FDA

According to the Food and Drug Administration (FDA), in the U.S. there are no scientific grounds for the medical use of use of marijuana and the agency is highly critical of attempts by individual states to legalise it.

23 Apr 2006

Australia's medicines regulator close to decision on herceptin

Australia's medicines regulator, the Therapeutic Goods Administration (TGA) is considering a recommendation by its expert committee, the Australian Drug Evaluation Committee (ADEC), to conditionally approve an application by Roche Products Pty Limited to extend the registration of the breast cancer drug Herceptin (trastuzumab) for use in HER2 positive localised breast cancer in addition to chemotherapy.

20 Apr 2006

New inhaled diabetic drug too costly for the NHS

The National Health Service in the UK seems to be staggering from one crisis to another and now another row has broken out over a new treatment for diabetes.

19 Apr 2006

New Medicare drug benefit is meeting or exceeding expectations

According to a new survey released by AARP, nearly eight-in-ten, (78 percent) of those enrolled in a Medicare prescription drug plan say they are satisfied.

13 Apr 2006

FDA investigates abortion pill death

It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.

12 Apr 2006

U.S. watchdog says Xenical should be withdrawn

A consumer watchdog group in the U.S., Public Citizen, has petitioned the U.S. Food and Drug Administration (FDA) to withdraw the prescription diet drug Xenical (orlistat) from the market; the group also want the FDA to refuse approval for the weight-loss pill to be made widely available over the counter.

11 Apr 2006

Skin patch to treat ADHD gets the green light

The Food and Drug Administration (FDA) in the U.S. has approved a skin patch to control attention deficit hyperactivity disorder (ADHD) in children.

10 Apr 2006

Nigeria approves misoprostol for use in hospitals and clinics

An old drug will gain a new use in Nigeria when misoprostol will be distributed for prevention and control of post-partum hemorrhage, the life-threatening bleeding after childbirth that commonly occurs in developing countries.

3 Apr 2006

ADHD drug not safe for kids

According to a panel of experts advising the U.S. Food and Drug Administration (FDA), the drug Provigil, although effective in treating attention deficit hyperactivity disorder (ADHD) in children and teenagers, is not safe enough to win approval.

26 Mar 2006

Asthma drug approved for children age four up

The U.S. Food and Drug Administration (FDA) has given approval for the use of the asthma drug Flovent HFA in children four to eleven years of age.

26 Mar 2006

Remicade (infliximab) gains Australian approval for treatment of early rheumatoid arthritis

Schering-Plough Corporation today announced that the Therapeutic Goods Administration of the Department of Health and Ageing in Australia has revised the indication of Remicade (infliximab) to include the treatment of early rheumatoid arthritis (RA) and approved a new indication for psoriatic arthritis (PsA).

23 Mar 2006